Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-03-27
2000-11-28
Ulm, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530399, 930120, A61K 3827, C07K 1461
Patent
active
061535818
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to a drug for recovering renal function. In particular, the present invention relates to a drug for treating progressive renal dysfunction in a patient with renal failure who has not yet undergone kidney dialysis.
BACKGROUND OF THE INVENTION
Presently, human growth hormone (referred to hereinafter as hGH) is used to treat pituitary dwarfism. In addition, it is also reported to be useful in acceleration of healing of bone fracture and burn wound, as well as in the treatment of patients of malnutrition (94/95 Nikkei Baio Nenkan). According to the following papers, hGH has been examined for its improving effect on the growth failure of short children having renal failure and also administrated to adult patients having renal failure. However, the papers only demonstrate the ameliorating effect of hGH on the malnourished conditions of patients who are undergoing dialysis, i.e., who have lost their renal functions. hormone treatment for patients with renal failure". "Improvement of malnutrition indices in adult patients with end stage renal disease by rhGH".
It has not been reported in the above papers that hGH may be useful for recovering progressive renal dysfunction in a patient with renal failure who has not yet undergone dialysis.
To date, there is not available a drug effective in maintaining or restoring the renal function of patients with end stage renal failure who have not yet undergone dialysis. Thus there is no way to prolong their lives except for such a treatment as renal dialysis or renal transplantation which is highly risky and burdensome to the patients.
SUMMARY OF INVENTION
The object of the present invention is to provide a drug for treating progressive renal dysfunction in a patient with renal failure who has not yet undergone dialysis. Such a drug allows patients to avoid or delay the start of kidney dialysis for patients with end stage renal failure. The method of the present invention may protect them from irreversible loss of renal function.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows observations during 60 weeks before and after hgH administration in Case 1 of Example 1. The line graph and the ordinate show the 1/Cr value (reciprocal of the serum creatinine concentration), and the numerals at the lower part of the graph show the CCR value (creatinine clearance) and the Ucr value (the amount of secreted creatinine in urine).
FIG. 2. shows observations during 60 weeks before and after the hgH administration in Case 2 of Example 2. The line graph and the ordinate show the 1/Cr value (reciprocal of the serum creatinine concentration), and the numerals at the lower part of the graph show the CCr value (creatinine clearance) and the Ucr value (the amount of secreted creatinine in urine).
FIG. 3. shows observations during 60 weeks before and 20 weeks after the hgH administration in Case 3 of Example 3. The line graph and the ordinate show the 1/Cr value (reciprocal of the serum creatinine concentration), and the numerals at the lower part of the graph show the CCr value (creatinine clearance) and the Ucr value (the amount of secreted creatinine in urine).
DETAILED DESCRIPTION OF THE PRESENT INVENTION
The present inventors have hitherto used hGH to ameliorate the nourishment of renal failure patients who undergo dialysis. Surprisingly, the inventors have now found that, when administered to renal failure patients who have not undergone dialysis, hGH can improve their renal function which had been steadily deteriorating until then, and can avoid the start of hemodialysis therapy (which starts based on blood 1/Cr value<0.1 dl/mg). The present invention has been accomplished on the basis of this finding.
Thus, the present invention relates to a drug for treating progressive renal dysfunction in a renal failure patient who has not yet undergone dialysis, which comprises hGH as an active ingredient. In addition, the present invention relates to a method for treating renal dysfunction in a renal failure patient who has not yet un
REFERENCES:
Sanaka, Tsutomu. "Long-Term Effect of Recombinant Human Growth Hormone (rhGH) on progression of End-Stage Renal Disease (ESRD)" Journal of the American Society of Nephrology; Sep. 1995, vol. 6, No. 3, p. 1030.
Ziegler, Thomas R. "Effects of Recombinant Human Growth Hormone in Adults Receiving Maintenance Hemodialysis." Journal of the American Society of Nephrology; 1991, vol. 2, No. 6, pp. 1130-1135.
Kopple, Joel D. "Growth hormone treatment for patients with renal failure." Japanese Journal of Nephrology; 1991, vol. 33, No. 5, pp. 468-474.
Andersson, Hans C. "Effect of growth hormone treatment on serum creatinine concentration in patients with cystinosis and chronic renal disease." The Journal of Pediatrics; May 1992, vol. 120, No. 5, vol. 6, No. 5, pp. 716-720.
Mehls et al. Acta Paediatr. Suppl. 399:81-87, 1994.
Guyton. Textbook of Medical Physiology, 8th ed. WB Sauders Co, pp. 344-348, 1991.
Saoud Christine
Sumitomo Pharmaceuticals Company
Ulm John
LandOfFree
Drug for recovering renal function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug for recovering renal function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug for recovering renal function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1725895